Trial Watch: Anticancer radioimmunotherapy
- PMID: 24319634
- PMCID: PMC3850274
- DOI: 10.4161/onci.25595
Trial Watch: Anticancer radioimmunotherapy
Abstract
Radiotherapy has extensively been employed as a curative or palliative intervention against cancer throughout the last century, with a varying degree of success. For a long time, the antineoplastic activity of X- and γ-rays was entirely ascribed to their capacity of damaging macromolecules, in particular DNA, and hence triggering the (apoptotic) demise of malignant cells. However, accumulating evidence indicates that (at least part of) the clinical potential of radiotherapy stems from cancer cell-extrinsic mechanisms, including the normalization of tumor vasculature as well as short- and long-range bystander effects. Local bystander effects involve either the direct transmission of lethal signals between cells connected by gap junctions or the production of diffusible cytotoxic mediators, including reactive oxygen species, nitric oxide and cytokines. Conversely, long-range bystander effects, also known as out-of-field or abscopal effects, presumably reflect the elicitation of tumor-specific adaptive immune responses. Ionizing rays have indeed been shown to promote the immunogenic demise of malignant cells, a process that relies on the spatiotemporally defined emanation of specific damage-associated molecular patterns (DAMPs). Thus, irradiation reportedly improves the clinical efficacy of other treatment modalities such as surgery (both in neo-adjuvant and adjuvant settings) or chemotherapy. Moreover, at least under some circumstances, radiotherapy may potentiate anticancer immune responses as elicited by various immunotherapeutic agents, including (but presumably not limited to) immunomodulatory monoclonal antibodies, cancer-specific vaccines, dendritic cell-based interventions and Toll-like receptor agonists. Here, we review the rationale of using radiotherapy, alone or combined with immunomodulatory agents, as a means to elicit or boost anticancer immune responses, and present recent clinical trials investigating the therapeutic potential of this approach in cancer patients.
Keywords: brachytherapy; immunogenic cell death; intensity-modulated radiation therapy; radionuclide; stereotactic body radiation therapy; stereotactic radiosurgery.
Similar articles
-
Ionizing radiation effects on the tumor microenvironment.Semin Oncol. 2019 Jun;46(3):254-260. doi: 10.1053/j.seminoncol.2019.07.003. Epub 2019 Jul 30. Semin Oncol. 2019. PMID: 31383368 Review.
-
Trial Watch: Radioimmunotherapy for oncological indications.Oncoimmunology. 2014 Dec 13;3(9):e954929. doi: 10.4161/21624011.2014.954929. eCollection 2014 Oct. Oncoimmunology. 2014. PMID: 25941606 Free PMC article. Review.
-
[Non-targeted effects (bystander, abscopal) of external beam radiation therapy: an overview for the clinician].Cancer Radiother. 2014 Dec;18(8):770-8. doi: 10.1016/j.canrad.2014.08.004. Epub 2014 Oct 14. Cancer Radiother. 2014. PMID: 25451674 Review. French.
-
Trial watch: Immunostimulatory cytokines in cancer therapy.Oncoimmunology. 2014 Jun 3;3:e29030. doi: 10.4161/onci.29030. eCollection 2014. Oncoimmunology. 2014. PMID: 25083328 Free PMC article.
-
Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.Oncologist. 1997;2(1):59-61. Oncologist. 1997. PMID: 10388030
Cited by
-
Cellular RNA and DNA sensing pathways are essential for the dose-dependent response of human monocytes to ionizing radiation.Front Immunol. 2023 Dec 12;14:1235936. doi: 10.3389/fimmu.2023.1235936. eCollection 2023. Front Immunol. 2023. PMID: 38152396 Free PMC article.
-
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis.Mol Ther Oncolytics. 2023 Apr 10;29:44-58. doi: 10.1016/j.omto.2023.04.001. eCollection 2023 Jun 15. Mol Ther Oncolytics. 2023. PMID: 37180034 Free PMC article.
-
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice.Oncoimmunology. 2022 Mar 25;11(1):2057892. doi: 10.1080/2162402X.2022.2057892. eCollection 2022. Oncoimmunology. 2022. PMID: 35355680 Free PMC article.
-
An ionising radiation-induced specific transcriptional signature of inflammation-associated genes in whole blood from radiotherapy patients: a pilot study.Radiat Oncol. 2021 May 3;16(1):83. doi: 10.1186/s13014-021-01807-4. Radiat Oncol. 2021. PMID: 33941218 Free PMC article.
-
Cancer stem cells and macrophages: molecular connections and future perspectives against cancer.Oncotarget. 2021 Feb 2;12(3):230-250. doi: 10.18632/oncotarget.27870. eCollection 2021 Feb 2. Oncotarget. 2021. PMID: 33613850 Free PMC article. Review.
References
-
- Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345:1378–87. doi: 10.1056/NEJMoa010874. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous